skip to Main Content

KIF20B Promotes Cell Proliferation and May Be a Potential Therapeutic Target in Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
Pancreatic cancer is a highly fatal disease in which mortality is closely related to the incidence [1]. Most pancreatic cancer patients remain asymptomatic until the disease is advanced. So, pancreatic cancer is one of the leading causes of fatal disease in cancer across the world [2]. The 5-year survival of patients with complete resection is only 25% [1]. The main types of pancreatic cancer are adenocarcinoma (85%) and endocrine carcinoma (less than 5%) [24]. According to the cancer statistics in 2018, about 55,440 people suffered from pancreatic cancer, and pancreatic cancer causes 44,330 deaths [5]. In 2017, there were 53,670 patients with pancreatic cancer and 43,090 patients died because of pancreatic cancer [6]. Pancreatic cancer was 11th common cancer in 2012 [2] but ranked 4th in 2018 of cancer statistics [5]. The five-year survival rate of pancreatic cancer is less than 5% [3]. In the last decades, the number of pancreatic cancer has been increased in both genders [79]. Early diagnosis is the key for improving survival.

The kinesin superfamily (KIF) proteins are highly conserved proteins with the motor domain, some of which move to the plus end of the microtubule in ATP, which depends on the adenosine triphosphatase activity [1012]. KIF family plays an important role in many essential biological processes, including mitosis, meiosis, and the transport of macromolecules. Read more . . . 

Back To Top